1. Tangri A, Lighty K, Loganathan J, Mesmar F, Podicheti R, Zhang C, Iwanicki M, Drapkin R, Nakshatri H, Mitra S.Mol Cancer Res. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma. 2021 Mar 22. doi: 10.1158/1541-7786.MCR-20-0883. Online ahead of print.PMID: 33753553

  2. Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P,Iwanicki M, Walker SR, Kanodia A, Melms JC, Mei S, Lin JR, Porter CBM, Slyper M, Waldman J, Jerby-Arnon L, Ashenberg O, Brinker TJ, Mills C, Rogava M, Vigneau S, Sorger PK, Garraway LA, Konstantinopoulos PA, Liu JF, Matulonis U, Johnson BE, Rozenblatt-Rosen O, Rotem A, Regev A. A Single-Cell Landscape of High-Grade Serous Ovarian Cancer Nat Med. 2020 Jun 22. doi: 10.1038/s41591-020-0926-0. Online ahead of print.PMID: 32572264

  3. Kozlova N, Grossman JE, Iwanicki MP, Muranen T. The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers. Trends Pharmacol Sci. 2020 Mar;41(3):183-198. doi: 10.1016/j.tips.2020.01.001. Epub 2020 Jan 31. Review. PubMed PMID: 32014341.

  4. Farsinejad S, Cattabiani T, Muranen T, Iwanicki M. Ovarian Cancer Dissemination-A Cell Biologist’s Perspective. Cancers (Basel). 2019 Dec 6;11(12). doi: 10.3390/cancers11121957. Review. PubMed PMID: 31817625; PubMed Central PMCID: PMC6966436.

  5. Zaborowski MP, Lee K, Na YJ, Sammarco A, Zhang X, Iwanicki M, Cheah PS, Lin HY, Zinter M, Chou CY, Fulci G, Tannous BA, Lai CP, Birrer MJ, Weissleder R, Lee H, Breakefield XO. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Rep. 2019 Apr 2;27(1):255-268.e6. doi: 10.1016/j.celrep.2019.03.003. PubMed PMID: 30943406; PubMed Central PMCID: PMC6528836.

  6. Eriksson M, Ambroise G, Ouchida AT, Lima Queiroz A, Smith D, Gimenez-Cassina A, Iwanicki MP, Muller PA, Norberg E, Vakifahmetoglu-Norberg H. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. Mol Cell Biol. 2017 Dec 15;37(24). doi: 10.1128/MCB.00328-17. Print 2017 Dec 15. PubMed PMID: 28993478; PubMed Central PMCID: PMC5705820.

  7. Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-Awar R, Neel BG, McPherson J, Drapkin R, Ailles L, Mes-Massons AM, Rottapel R. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Rep. 2017 Mar 7;18(10):2343-2358. doi: 10.1016/j.celrep.2017.02.028. PubMed PMID: 28273451.

  8. Muranen T, Iwanicki MP, Curry NL, Hwang J, DuBois CD, Coloff JL, Hitchcock DS, Clish CB, Brugge JS, Kalaany NY. Starved epithelial cells uptake extracellular matrix for survival. Nat Commun. 2017 Jan 10;8:13989. doi: 10.1038/ncomms13989. PubMed PMID: 28071763; PubMed Central PMCID: PMC5234072.

  9. Sheets JN, Iwanicki M, Liu JF, Howitt BE, Hirsch MS, Gubbels JA, Drapkin R, Egland KA. SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis. 2016 Oct 24;5(10):e264. doi: 10.1038/oncsis.2016.64. PubMed PMID: 27775699; PubMed Central PMCID: PMC5117850.

  10. Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS. Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight. 2016 Jul 7;1(10). doi: 10.1172/jci.insight.86829. PubMed PMID: 27482544; PubMed Central PMCID: PMC4963159.

  11. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review. PubMed PMID: 26493647; PubMed Central PMCID: PMC4892184.

  12. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest. 2014 Jun;124(6):2611-25. doi: 10.1172/JCI69815. Epub 2014 Apr 24. PubMed PMID: 24762435; PubMed Central PMCID: PMC4038562.

  13. Maninová M, Iwanicki MP, Vomastek T. Emerging role for nuclear rotation and orientation in cell migration. Cell Adh Migr. 2014;8(1):42-8. doi: 10.4161/cam.27761. Epub 2013 Jan 1. PubMed PMID: 24589621 ; PubMed Central PMCID: PMC3974792.

  14. Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA. Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. PLoS One. 2013;8(11):e80314. doi: 10.1371/journal.pone.0080314. eCollection 2013. PubMed PMID: 24303006; PubMed Central PMCID: PMC3841174.

  15. Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, Pan L, Ince TA, Kroemer G, Brugge JS, Yuan J. Chaperone-mediated autophagy degrades mutant p53. Genes Dev. 2013 Aug 1;27(15):1718-30. doi: 10.1101/gad.220897.113. PubMed PMID: 23913924; PubMed Central PMCID: PMC3744729.

  16. Maninová M, Klímová Z, Parsons JT, Weber MJ, Iwanicki MP, Vomastek T. The reorientation of cell nucleus promotes the establishment of front-rear polarity in migrating fibroblasts. J Mol Biol. 2013 Jun 12;425(11):2039-2055. doi: 10.1016/j.jmb.2013.02.034. Epub 2013 Mar 21. PubMed PMID: 23524135.

  17. Davidowitz RA, Iwanicki MP, Brugge JS. In vitro mesothelial clearance assay that models the early steps of ovarian cancer metastasis. J Vis Exp. 2012 Feb 17;(60). doi: 10.3791/3888. PubMed PMID: 22371143; PubMed Central PMCID: PMC3466628.

  18. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 2012 Feb 14;21(2):227-39. doi: 10.1016/j.ccr.2011.12.024. PubMed PMID: 22340595; PubMed Central PMCID: PMC3297962.

  19. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince TA, Brugge JS. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011 Jul;1(2):144-57. doi: 10.1158/2159-8274.CD-11-0010. PubMed PMID: 22303516; PubMed Central PMCID: PMC3269166.

  20. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009 Dec 24;139(7):1327-41. doi: 10.1016/j.cell.2009.11.026. PubMed PMID: 20064378.

  21. Iwanicki MP, Brugge JS. Transcriptional regulation of metastatic [Id]entity by KLF17. Genome Biol. 2009;10(11):244. doi: 10.1186/gb-2009-10-11-244. Epub 2009 Nov 30. Review. PubMed PMID: 19951400; PubMed Central PMCID: PMC3091312.

  22. Vomastek T, Iwanicki MP, Burack WR, Tiwari D, Kumar D, Parsons JT, Weber MJ, Nandicoori VK. Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction. Mol Cell Biol. 2008 Nov;28(22):6954-66. doi: 10.1128/MCB.00925-08. Epub 2008 Sep 15. PubMed PMID: 18794356; PubMed Central PMCID: PMC2573295.

  23. Iwanicki MP, Vomastek T, Tilghman RW, Martin KH, Banerjee J, Wedegaertner PB, Parsons JT. FAK, PDZ-RhoGEF and ROCKII cooperate to regulate adhesion movement and trailing-edge retraction in fibroblasts. J Cell Sci. 2008 Mar 15;121(Pt 6):895-905. doi: 10.1242/jcs.020941. Epub 2008 Feb 26. PubMed PMID: 18303050.

  24. Vomastek T, Iwanicki MP, Schaeffer HJ, Tarcsafalvi A, Parsons JT, Weber MJ. RACK1 targets the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to link integrin engagement with focal adhesion disassembly and cell motility. Mol Cell Biol. 2007 Dec;27(23):8296-305. doi: 10.1128/MCB.00598-07. Epub 2007 Oct 1. PubMed PMID: 17908799; PubMed Central PMCID: PMC2169169.

  25. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. doi: 10.1074/jbc.M606695200. Epub 2007 Mar 28. PubMed PMID: 17395594.

  26. Tilghman RW, Slack-Davis JK, Sergina N, Martin KH, Iwanicki M, Hershey ED, Beggs HE, Reichardt LF, Parsons JT. Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J Cell Sci. 2005 Jun 15;118(Pt 12):2613-23. doi: 10.1242/jcs.02380. Epub 2005 May 24. PubMed PMID: 15914540; NIHMSID:NIHMS112405.

  27. Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, Cohen OJ, vanCott TC, Iwanicki M, Lewis MG, Greenhouse J, Barry T, Venzon D, Fauci AS. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med. 2001 Nov;7(11):1225-31. doi: 10.1038/nm1101-1225. PubMed PMID: 11689887.